Dynavax Technologies Corporation Logo

Dynavax Technologies Corporation

DVAX

(1.5)
Stock Price

11,50 USD

6.3% ROA

-1.08% ROE

29.47x PER

Market Cap.

1.805.129.865,00 USD

41.84% DER

0% Yield

-2.75% NPM

Dynavax Technologies Corporation Stock Analysis

Dynavax Technologies Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Dynavax Technologies Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (42%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE falls within an average range (10.51%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (6.3%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 PBV

The stock's PBV ratio (2.88x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

5 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (92), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Dynavax Technologies Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Dynavax Technologies Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Dynavax Technologies Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Dynavax Technologies Corporation Revenue
Year Revenue Growth
2000 0
2001 2.359.000 100%
2002 1.427.000 -65.31%
2003 826.000 -72.76%
2004 14.812.000 94.42%
2005 14.655.000 -1.07%
2006 4.847.000 -202.35%
2007 14.093.000 65.61%
2008 37.094.000 62.01%
2009 40.318.000 8%
2010 23.950.000 -68.34%
2011 21.614.000 -10.81%
2012 9.714.000 -122.5%
2013 11.251.000 13.66%
2014 11.032.000 -1.99%
2015 4.050.000 -172.4%
2016 11.043.000 63.33%
2017 327.000 -3277.06%
2018 8.198.000 96.01%
2019 35.219.000 76.72%
2020 46.551.000 24.34%
2021 439.442.000 89.41%
2022 722.683.000 39.19%
2023 278.056.000 -159.91%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Dynavax Technologies Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2000 8.267.000
2001 17.363.000 52.39%
2002 15.965.000 -8.76%
2003 14.381.000 -11.01%
2004 23.129.000 37.82%
2005 27.887.000 17.06%
2006 50.116.000 44.36%
2007 65.888.000 23.94%
2008 44.771.000 -47.17%
2009 38.708.000 -15.66%
2010 53.680.000 27.89%
2011 51.322.000 -4.59%
2012 49.146.000 -4.43%
2013 50.870.000 3.39%
2014 84.580.000 39.86%
2015 86.943.000 2.72%
2016 84.493.000 -2.9%
2017 64.988.000 -30.01%
2018 74.951.000 13.29%
2019 62.331.000 -20.25%
2020 28.607.000 -117.89%
2021 32.228.000 11.24%
2022 46.600.000 30.84%
2023 56.464.000 17.47%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Dynavax Technologies Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 8.543.000 100%
2005 9.258.000 7.72%
2006 14.836.000 37.6%
2007 18.293.000 18.9%
2008 15.463.000 -18.3%
2009 15.745.000 1.79%
2010 16.879.000 6.72%
2011 17.570.000 3.93%
2012 28.164.000 37.62%
2013 26.869.000 -4.82%
2014 17.763.000 -51.26%
2015 22.180.000 19.91%
2016 37.257.000 40.47%
2017 27.367.000 -36.14%
2018 64.770.000 57.75%
2019 0 0%
2020 79.256.000 100%
2021 100.156.000 20.87%
2022 131.408.000 23.78%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Dynavax Technologies Corporation EBITDA
Year EBITDA Growth
2000 -11.718.000
2001 -19.531.000 40%
2002 -17.981.000 -8.62%
2003 -17.188.000 -4.61%
2004 -13.587.000 -26.5%
2005 -19.358.000 29.81%
2006 -55.091.000 64.86%
2007 -70.088.000 21.4%
2008 -26.290.000 -166.6%
2009 -12.278.000 -114.12%
2010 -37.044.000 66.86%
2011 -46.809.000 20.86%
2012 -67.598.000 30.75%
2013 -65.161.000 -3.74%
2014 -90.687.000 28.15%
2015 -104.551.000 13.26%
2016 -110.707.000 5.56%
2017 -89.245.000 -24.05%
2018 -149.561.000 40.33%
2019 -114.767.000 -30.32%
2020 -67.153.000 -70.9%
2021 142.283.000 147.2%
2022 298.230.000 52.29%
2023 59.348.000 -402.51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Dynavax Technologies Corporation Gross Profit
Year Gross Profit Growth
2000 0
2001 2.359.000 100%
2002 1.427.000 -65.31%
2003 826.000 -72.76%
2004 14.812.000 94.42%
2005 14.655.000 -1.07%
2006 4.149.000 -253.22%
2007 13.089.000 68.3%
2008 36.114.000 63.76%
2009 39.338.000 8.2%
2010 22.970.000 -71.26%
2011 21.315.000 -7.76%
2012 9.714.000 -119.43%
2013 11.251.000 13.66%
2014 11.032.000 -1.99%
2015 4.050.000 -172.4%
2016 11.043.000 63.33%
2017 -867.000 1373.7%
2018 -13.598.000 93.62%
2019 15.830.000 185.9%
2020 32.641.000 51.5%
2021 265.870.000 87.72%
2022 460.530.000 42.27%
2023 225.140.000 -104.55%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Dynavax Technologies Corporation Net Profit
Year Net Profit Growth
2000 -26.724.000
2001 -18.412.000 -45.14%
2002 -18.038.000 -2.07%
2003 -17.352.000 -3.95%
2004 -15.971.000 -8.65%
2005 -20.555.000 22.3%
2006 -52.052.000 60.51%
2007 -59.971.000 13.2%
2008 -20.829.000 -187.92%
2009 -30.565.000 31.85%
2010 -57.308.000 46.67%
2011 -48.597.000 -17.92%
2012 -69.949.000 30.53%
2013 -66.720.000 -4.84%
2014 -90.722.000 26.46%
2015 -106.794.000 15.05%
2016 -112.444.000 5.02%
2017 -95.154.000 -18.17%
2018 -158.899.000 40.12%
2019 -151.397.000 -4.96%
2020 -91.776.000 -64.96%
2021 76.713.000 219.64%
2022 293.156.000 73.83%
2023 57.172.000 -412.76%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Dynavax Technologies Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -226
2001 -123 -84.43%
2002 -106 -15.09%
2003 -97 -10.42%
2004 -8 -1271.43%
2005 -8 0%
2006 -16 56.25%
2007 -15 -6.67%
2008 -5 -200%
2009 -8 28.57%
2010 -7 -16.67%
2011 -4 -100%
2012 -4 25%
2013 -3 -33.33%
2014 -3 0%
2015 -3 0%
2016 -3 -50%
2017 -2 -100%
2018 -3 50%
2019 -2 0%
2020 -1 0%
2021 1 0%
2022 3 100%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Dynavax Technologies Corporation Free Cashflow
Year Free Cashflow Growth
2002 -14.751.000
2003 -14.544.000 -1.42%
2004 -9.195.000 -58.17%
2005 -23.420.000 60.74%
2006 -38.365.000 38.95%
2007 -35.679.000 -7.53%
2008 -21.133.000 -68.83%
2009 -33.929.000 37.71%
2010 -51.790.000 34.49%
2011 -48.258.000 -7.32%
2012 -46.740.000 -3.25%
2013 -60.302.000 22.49%
2014 -75.405.000 20.03%
2015 -99.529.000 24.24%
2016 -114.808.000 13.31%
2017 -78.187.000 -46.84%
2018 -146.488.000 46.63%
2019 -150.653.000 2.76%
2020 -103.323.000 -45.81%
2021 326.051.000 131.69%
2022 55.577.000 -486.67%
2023 659.000 -8333.54%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Dynavax Technologies Corporation Operating Cashflow
Year Operating Cashflow Growth
2002 -14.283.000
2003 -14.406.000 0.85%
2004 -7.332.000 -96.48%
2005 -22.858.000 67.92%
2006 -37.240.000 38.62%
2007 -32.032.000 -16.26%
2008 -17.035.000 -88.04%
2009 -33.552.000 49.23%
2010 -51.370.000 34.69%
2011 -47.116.000 -9.03%
2012 -43.809.000 -7.55%
2013 -58.673.000 25.33%
2014 -73.738.000 20.43%
2015 -92.559.000 20.33%
2016 -107.051.000 13.54%
2017 -77.518.000 -38.1%
2018 -131.301.000 40.96%
2019 -121.252.000 -8.29%
2020 -92.251.000 -31.44%
2021 335.528.000 127.49%
2022 62.716.000 -435%
2023 659.000 -9416.84%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Dynavax Technologies Corporation Capital Expenditure
Year Capital Expenditure Growth
2002 468.000
2003 138.000 -239.13%
2004 1.863.000 92.59%
2005 562.000 -231.49%
2006 1.125.000 50.04%
2007 3.647.000 69.15%
2008 4.098.000 11.01%
2009 377.000 -987%
2010 420.000 10.24%
2011 1.142.000 63.22%
2012 2.931.000 61.04%
2013 1.629.000 -79.93%
2014 1.667.000 2.28%
2015 6.970.000 76.08%
2016 7.757.000 10.15%
2017 669.000 -1059.49%
2018 15.187.000 95.59%
2019 29.401.000 48.35%
2020 11.072.000 -165.54%
2021 9.477.000 -16.83%
2022 7.139.000 -32.75%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Dynavax Technologies Corporation Equity
Year Equity Growth
2000 -17.999.000
2001 -34.417.000 47.7%
2002 -56.371.000 38.95%
2003 -71.932.000 21.63%
2004 59.876.000 220.13%
2005 74.363.000 19.48%
2006 77.056.000 3.49%
2007 30.790.000 -150.26%
2008 13.522.000 -127.7%
2009 6.376.000 -112.08%
2010 52.111.000 87.76%
2011 99.880.000 47.83%
2012 114.826.000 13.02%
2013 186.294.000 38.36%
2014 100.482.000 -85.4%
2015 187.079.000 46.29%
2016 89.201.000 -109.73%
2017 199.549.000 55.3%
2018 63.065.000 -216.42%
2019 8.290.000 -660.74%
2020 58.693.000 85.88%
2021 222.374.000 73.61%
2022 581.013.000 61.73%
2023 604.916.000 3.95%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Dynavax Technologies Corporation Assets
Year Assets Growth
2000 29.590.000
2001 15.117.000 -95.74%
2002 31.478.000 51.98%
2003 31.585.000 0.34%
2004 73.646.000 57.11%
2005 80.093.000 8.05%
2006 102.890.000 22.16%
2007 120.449.000 14.58%
2008 90.623.000 -32.91%
2009 50.470.000 -79.56%
2010 84.249.000 40.09%
2011 134.102.000 37.18%
2012 139.752.000 4.04%
2013 204.622.000 31.7%
2014 138.290.000 -47.97%
2015 216.633.000 36.16%
2016 109.680.000 -97.51%
2017 218.785.000 49.87%
2018 210.884.000 -3.75%
2019 279.068.000 24.43%
2020 353.272.000 21%
2021 1.039.246.000 66.01%
2022 985.850.000 -5.42%
2023 972.933.000 -1.33%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Dynavax Technologies Corporation Liabilities
Year Liabilities Growth
2000 47.589.000
2001 49.534.000 3.93%
2002 87.849.000 43.61%
2003 88.784.000 1.05%
2004 13.770.000 -544.76%
2005 5.730.000 -140.31%
2006 23.818.000 75.94%
2007 81.318.000 70.71%
2008 74.467.000 -9.2%
2009 44.094.000 -68.88%
2010 32.138.000 -37.2%
2011 34.222.000 6.09%
2012 24.926.000 -37.29%
2013 18.328.000 -36%
2014 37.808.000 51.52%
2015 29.554.000 -27.93%
2016 20.479.000 -44.31%
2017 19.236.000 -6.46%
2018 147.819.000 86.99%
2019 270.778.000 45.41%
2020 294.579.000 8.08%
2021 816.872.000 63.94%
2022 404.837.000 -101.78%
2023 368.017.000 -10%

Dynavax Technologies Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.8
Net Income per Share
0.47
Price to Earning Ratio
29.47x
Price To Sales Ratio
5x
POCF Ratio
19.74
PFCF Ratio
20.59
Price to Book Ratio
2.98
EV to Sales
5.27
EV Over EBITDA
23.16
EV to Operating CashFlow
20.86
EV to FreeCashFlow
21.72
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
1,81 Bil.
Enterprise Value
1,90 Bil.
Graham Number
7.07
Graham NetNet
3.2

Income Statement Metrics

Net Income per Share
0.47
Income Quality
1.95
ROE
0.11
Return On Assets
-0.01
Return On Capital Employed
-0.03
Net Income per EBT
1.46
EBT Per Ebit
0.18
Ebit per Revenue
-0.11
Effective Tax Rate
-0.46

Margins

Sales, General, & Administrative to Revenue
0.29
Research & Developement to Revenue
0.15
Stock Based Compensation to Revenue
0.08
Gross Profit Margin
0.78
Operating Profit Margin
-0.11
Pretax Profit Margin
-0.02
Net Profit Margin
-0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.71
Free CashFlow per Share
0.68
Capex to Operating CashFlow
-0.04
Capex to Revenue
-0.01
Capex to Depreciation
-0.74
Return on Invested Capital
0.05
Return on Tangible Assets
0.06
Days Sales Outstanding
47.36
Days Payables Outstanding
9.57
Days of Inventory on Hand
151.6
Receivables Turnover
7.71
Payables Turnover
38.13
Inventory Turnover
2.41
Capex per Share
-0.03

Balance Sheet

Cash per Share
5,59
Book Value per Share
4,69
Tangible Book Value per Share
4.67
Shareholders Equity per Share
4.69
Interest Debt per Share
2.01
Debt to Equity
0.42
Debt to Assets
0.26
Net Debt to EBITDA
1.2
Current Ratio
15.4
Tangible Asset Value
0,60 Bil.
Net Current Asset Value
0,47 Bil.
Invested Capital
0.42
Working Capital
0,78 Bil.
Intangibles to Total Assets
0
Average Receivables
0,05 Bil.
Average Payables
0,00 Bil.
Average Inventory
51250000
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Dynavax Technologies Corporation Dividends
Year Dividends Growth

Dynavax Technologies Corporation Profile

About Dynavax Technologies Corporation

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

CEO
Mr. Ryan Spencer
Employee
408
Address
2100 Powell Street
EmeryVille, 94608

Dynavax Technologies Corporation Executives & BODs

Dynavax Technologies Corporation Executives & BODs
# Name Age
1 Mr. Jeff P. Coon
CHRO and Senior Vice President of Human Resources & Administration
70
2 Mr. Donn Casale
Chief Commercial Officer
70
3 Mr. Paul Cox
Vice President of Investor Relations & Corporate Communications
70
4 Dr. Dong Yu
Senior Vice President of Vaccine Research
70
5 Mr. David F. Novack
President & Chief Operating Officer
70
6 Dr. Robert Janssen
Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs
70
7 Mr. Justin Burgess
Principal Accounting Officer & Controller
70
8 Mr. John Slebir
Senior Vice President & General Counsel
70
9 Mr. Ryan Spencer
Chief Executive Officer & Director
70
10 Ms. Kelly MacDonald
Senior Vice President & Chief Financial Officer
70

Dynavax Technologies Corporation Competitors